Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10399498 | 0.90 | ADORA2A (0.57) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL9761653 | 0.86 | ADORA2A (0.70) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL9761625 | 0.86 | ADORA2A (0.70) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL9763034 | 0.86 | ADORA2A (0.70) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL10399798 | 0.83 | PGK1 (0.70) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL10399407 | 0.82 | CYP1A2 (0.72) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL10399357 | 0.81 | ADORA2A (0.68) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL9793357 | 0.81 | ADORA3 (0.86) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL9793385 | 0.81 | ADORA3 (0.86) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL4754960 | 0.81 | ADORA3 (0.86) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4977144-A | ADENOSINE AGONISTS | CIBA-GEIGY CORPORATION (US) | 1990-12-11 | — | — | US | disclosed |
| EP-0354180-A2 | Certain imidazo[4,5-b]pyridine derivatives | CIBA-GEIGY AG (CH) | 1990-02-07 | — | — | EP | disclosed |